Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study of RX-10100 in Subjects With Major Depressive Disorder.
NCT01273376 is registered in ClinicalTrials.gov with Rexahn Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study of RX-10100 in Subjects With Major Depressive Disorder.
- Lead sponsor
- Rexahn Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2010
- Completion date
- October 31, 2011
- Enrollment
- 314 (actual)
- Sites
- 44
Conditions
As the registry lists them; a condition with its own page is linked.